Clinical Trials

See all trials

5 studies in Department of Psychiatry and Psychology in Rochester, MN.

  1. DNA Repository for Addictions
    Rochester, Minn. View Summary

    DNA Repository for Addictions

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    This resource will be used to study variation in DNA possibly associated with developing addiction and response to treatment.

    IRB Number:

    2681-04

    Who can I contact for additional information about this study?

    Addictions Study Coordinator, 1-877-751-6444 (toll-free), psychaddiction@mayo.edu
  2. Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt
    Rochester, Minn. View Summary

    Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    Study hypothesis: Do serial low-dose ketamine infusions, followed by weekly maintenance infusions, increase the length of time depressive symptoms stay in remission and the length of time associated suicide risk is improved? Brief Summary: This open label clinical trial is intended to further clarify initial response to low-dose ketamine infusion with repeated dosing and maintenance treatment model. Primary outcomes will be reduction in depression severity and reduction of suicide risk along with duration of response.

    NCT ID:

    NCT02094898

    IRB Number:

    13-005152

    Who can I contact for additional information about this study?

    Rochester: Timothy W Lineberry, MD
                        


  3. Longitudinal Study of Cognition With Niemann-Pick Disease, Type C
    Rochester, Minn. View Summary

    Longitudinal Study of Cognition With Niemann-Pick Disease, Type C

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    Niemann-Pick Disease, Type C (NPC) is a rare neurodegenerative disorder with a wide clinical spectrum and variable age of onset. Classically, children with NPC demonstrate neurological dysfunction with cerebellar ataxia (an inability to coordinate balance, gait, extremity and eye movements), dysarthria (difficulty speaking), seizures, vertical gaze palsy (ability to move eyes in the same direction) motor impairment, dysphagia (trouble swallowing), psychotic episodes, and progressive dementia. There is no curative treatment for NPC and it is a lethal disorder. The purpose of this protocol is to obtain both baseline and rate of progression data on a clinical and biochemical markers that may later be used as outcome measures in a clinical trial. Specifically, this study will examine and characterize the longitudinal progression of neurocognitive symptoms of NPC with the goal of identifying early markers of disease progression that may be utilized in later trials to evaluate treatment efficacy.

    NCT ID:

    NCT01899950

    IRB Number:

    11-003868

    Who can I contact for additional information about this study?

    Rochester: Marc Patterson, MD 507-284-3351
                        


  4. Pharmacologic Dissection of Vestibular Migraine and Chronic Subjective Dizziness: A Double-Blind Parallel Group Trial Comparing Response to Verapamil Versus Sertraline
    Rochester, Minn., Phoenix/Scottsdale, Ariz. View Summary

    Pharmacologic Dissection of Vestibular Migraine and Chronic Subjective Dizziness: A Double-Blind Parallel Group Trial Comparing Response to Verapamil Versus Sertraline

    Location:

    Rochester, Minn., Phoenix/Scottsdale, Ariz.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    Chronic dizziness and recurrent vertigo are frequent complaints in primary and specialty medical care settings. Two common causes of these symptoms are vestibular migraine (VM) and chronic subjective dizziness (CSD), which may be seen in up to 25% of patients examined in tertiary neurotology centers. However, VM and CSD are relatively new diagnoses that have not yet been validated. Furthermore, recent research found that they co-exist 30% of the time with overlap in several features. From a clinical standpoint, this makes it difficult to diagnose and treat them well. From a research standpoint, it confounds subject selection for mechanistic investigations. The primary goal of this study to dissect VM and CSD in order to identify the key features and clarify the diagnostic criteria of each condition. Fifty patients diagnosed with coexisting VM-CSD will be treated with either verapamil or sertraline. Based on clinical and research experience to date, verapamil is thought to have greater effect on migraine-related symptoms, whereas sertraline is thought to have greater effect on CSD-related symptoms. It is hypothesized that a differential treatment response to these two pharmacologic probes will help to tease apart the unique clinical features of VM and CSD and identify risk factors that are shared or separate between the two conditions. The different mechanisms of action of the two study medications may also shed light on the physiologic underpinnings of VM and CSD. This project will be a 14-week, prospective, randomized, double-blind, parallel group, pharmacologic dissection trial. A 12-week treatment period will follow 2 weeks of baseline observation. Patients will chart daily headache and vestibular symptoms. VM and CSD symptoms and potential confounds such as anxiety and depression will be measured at two week intervals. Data will be analyzed for differential and shared treatment effects that align with or oppose current concepts of VM and CSD.

    NCT ID:

    NCT01669304

    IRB Number:

    12-002814

    Who can I contact for additional information about this study?

    Rochester: Jeffrey P Staab, MD 507-284-4159
                        Sherrie M Hanna 507-538-8341


  5. Support Person Effectiveness Study to Promote Smoker Utilization of the QUITPLAN Helpline
    Rochester, Minn. View Summary

    Support Person Effectiveness Study to Promote Smoker Utilization of the QUITPLAN Helpline

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    This study is being done to learn the helpfulness of a telephone-based program for support persons living in MN who are worried about a cigarette smoker living in MN.  This study will help support person learn new ways to be supportive as well as encourage a smoker to call the QUITPLAN Helpline.  The QUITPLAN Helpline is the tobacco Helpline for the state of Minnesota.  Research shows that Helpline?s are an effective way for smokers to quit or make a plan to quit.  The person you want to support does not need to be interested in or even thinking about quitting smoking in order for you to be in the study.   If the smoker does choose to call QUITPLAN, they are eligible for free services (counseling and/or nicotine replacement therapy) for seven months.  The seven months starts on the date of support person enrolling into our study.

    IRB Number:

    11-001796

    Who can I contact for additional information about this study?

    Christina Smith
    800.957.2950 toll-free
    507.538.8210 local
    supportpersonstudy@mayo.edu